Document:

Amendment to Development, Commercialization and Supply License Agreement

 Exhibit 10.37 
  
 January 28, 2004 
  
 BY FACSIMILE AND EXPRESS MAIL 
 CONFIDENTIAL 
 Peter A. Lankau 
 President 
 Endo Pharmaceuticals Inc. 
 100 Painters Drive 
 Chadds Ford, PA 19317 
  
 Re: Amendment to Development, Commercialization and Supply License Agreement 
  
 Dear Peter: 
  
 Reference is made to the Development, Commercialization and Supply License Agreement between Endo Pharmaceuticals Inc. (“Endo”) and DURECT Corporation (“DURECT”) effective November 8, 2002
(“Agreement”). Effective on the date written above, Endo and DURECT hereby agree as follows: 
  

	 	1.	 	Amendment to Section 4.6(a). Section 4.6(a) of the Agreement shall be amended to change “June 30, 2004” to “January 1, 2005”. 

  

	 	2.	 	Restatement of Section 4.6(c). Section 4.6(c) of the Agreement shall be deleted in its entirety, and in lieu thereof, the following shall be inserted:

  
 “(c) Notwithstanding anything to the
contrary in Sections 4.6(a) and (b) and except as set forth in this Section 4.6(c), Endo shall have no obligations under Sections 4.6(a) and (b) to make any payments to DURECT for any Developments Costs incurred up to and including the date on which
the first patient is dosed with the Product in the first clinical trial of at least that number of patients necessary to satisfy the FDA which occurs after the Effective Date (such date, the “Trial Commencement Date” and such trial,
the “First Trial”). Notwithstanding the foregoing: (i) in the event the Trial Commencement Date has not occurred by December 31, 2003, then during the period commencing on January 1, 2004 until the earlier of the Trial Commencement
Date or January 1, 2005, Endo shall be responsible for 25% of the Development Costs incurred in each such calendar month, up to an aggregate payment by Endo to DURECT of $250,000 of Development Costs for such period; and (ii) in the event the

 Trial Commencement Date has not occurred on or before January 1, 2005, then Endo shall be responsible for
such portion of the Development Costs incurred after January 1, 2005 in accordance with Section 4.6(a). Furthermore, until the Trial Commencement Date, DURECT hereby agrees to initiate any human trial only if such trial and the initiation thereof is
consistent with a reasonable pharmaceutical company’s overall global strategic development plan for a product similarly situated to the Product. Finally, in no event shall Endo be liable for any costs associated with any human pharmacokinetic
(PK) study undertaken by DURECT prior to the earlier of the Trial Commencement Date or January 1, 2005.” 
  

	 	3.	 	Restatement of Section 13.3(d). Section 13.3(d) of the Agreement shall be deleted in its entirety, and in lieu thereof, the following shall be inserted:

  
 “(d) [INTENTIONALLY OMITTED.]”

  

	 	4.	 	Restatement of Section 13.3(e). Section 13.3(e) of the Agreement shall be deleted in its entirety, and in lieu thereof, the following shall be inserted:

  
 “(e) In the event that the Trial
Commencement Date shall not have occurred on or before January 1, 2005, Endo shall have the right to terminate this Agreement effective upon 10 days’ written notice with no further rights or obligations hereunder (other than those rights or
obligations which are expressly indicated herein to survive termination or expiration of this Agreement); provided that such written notice is delivered to DURECT no later than January 31, 2005.” 
  

	 	5.	 	New Section 4.10. A new Section 4.10 shall be added to the Agreement as follows: 

  
 “4.10 Retention of Key Personnel. DURECT shall use its reasonable efforts to retain key personnel involved with
the development of the Product. Such key personnel shall be those individuals identified as such by the JEC. In the event that a member of the key personnel leaves the employ of DURECT (either on his/her own volition or otherwise), DURECT shall,
within three (3) business days of such departure, inform Endo of (1) such fact and (2) DURECT’s plan as to how it intends to address the departure of such key personnel to ensure the smooth continuance of the Development Program.” 

 Except as set forth above, all other terms of the Agreement shall remain the same. 
 Please sign below to indicate Endo’s agreement to the foregoing. 
  

	
	 Very truly yours,

	
	 /s/ James E. Brown

	 James E. Brown

	 President and CEO

  

			
	 AGREED TO BY ENDO:

		
	 By:
	 	 /s/ Peter A. Lankau

	 	 	 Peter A. Lankau

	 	 	 President

		
	 Date:
	 	 January 29, 2004Amendment to Joint Venture Partnership Agreement

 EXHIBIT 10.124 
  
 AMENDMENT TO AND CLARIFICATION OF JOINT VENTURE 
 PARTNERSHIP AGREEMENT OF FUND VIII-IX-REIT JOINT VENTURE 
 AND AGENCY AGREEMENT

 AMENDMENT TO AND CLARIFICATION OF JOINT VENTURE 
 PARTNERSHIP AGREEMENT OF FUND VIII-IX-REIT JOINT VENTURE 
 AND AGENCY AGREEMENT 
  
 This Amendment to and Clarification of Joint Venture Partnership Agreement of Fund VIII-IX-REIT Joint Venture and Agency Agreement (“this Agreement”) is made and entered into this 24th day of November, 2003, to be effective as of June 15, 2000, by and between WELLS OPERATING PARTNERSHIP, L.P. (“Wells OP”) and FUND VIII AND FUND IX
ASSOCIATES (the “Fund VIII-IX Joint Venture”). 
  
 W I
T N E S S E T H: 
  
 WHEREAS, the parties hereto have
previously entered into that certain Joint Venture Partnership Agreement (the “Joint Venture Agreement”) dated as of June 15, 2000, relating to the ownership and operation of that certain property located at 15253 Bake Parkway in Orange
County, California (the “Bake Parkway Property”); and 
  
 WHEREAS, the parties hereto desire to clarify and correct certain provisions of the Joint Venture Agreement relating to the ownership of the Bake Parkway Property. 
  
 NOW THEREFORE, for and in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto
covenant and agree, and the Joint Venture Agreement is hereby amended, as follows: 
  
 1. 
  
 Capitalized words used
herein shall have the meaning assigned to them in the Joint Venture Agreement unless the context clearly requires otherwise. 
  
 2. 
  
 Record title to the Bake Parkway Property is held in the name of the Fund VIII-IX Joint Venture. The parties hereto authorize and direct that title to the
Bake Parkway Property continue to be held in the name of the Fund VIII-IX Joint Venture as agent and nominee for and as an accommodation to the Venture and the Venturers. The Fund VIII-IX Joint Venture hereby acknowledges and agrees that title shall
be held subject to the authorization and direction of the Venturers in accordance with the terms and provisions of the Joint Venture Agreement as if record title were held in the name of the Venture. Wells OP, as the Administrative Venturer of this
Venture, is authorized to take such action on behalf of the Venture as may be approved by the Venturers in accordance with the terms and conditions of the Joint Venture Agreement. 
  
 The parties hereto hereby acknowledge and agree as follows: (i) that the Fund VIII-IX Joint Venture is acting strictly as
agent for the Venture in connection with holding title to the Bake Parkway Property pursuant to the terms of this Agreement; (ii) 
  

 that the Venture will be deemed the true owner of the Baker Parkway Property for tax and all other purposes; (iii) that
the Fund VIII-IX Joint Venture is functioning as agent, and not as principal, with respect to the Bake Parkway Property in all dealings with third parties; (iv) that the Fund VIII-IX Joint Venture will not convey, assign or encumber the Bake Parkway
Property unless directed to do so by the Venture, and that the Fund VIII-IX Joint Venture will convey, assign or encumber the Bake Parkway Property and disburse the proceeds only as specifically directed by the Venture; and (v) that the Venture
hereby indemnifies and holds the Fund VIII-IX Joint Venture harmless from any liability it might sustain for acting as its agent and nominee hereunder. 
  
 3. 
  
 Section 3.1 of the Joint Venture Agreement as hereby amended and restated in its entirety as follows: 
  
 3.1 Capital Contributions. The Fund VIII-IX Joint Venture shall be
obligated and required to contribute the Bake Parkway Property to the Venture, along with any and all leases and other contracts relating to the Bake Parkway Property, to be transferred and deeded to the Venture as its Capital Contribution to the
Venture. All real estate transfer taxes, deed taxes and other costs and expenses associated with the transfer of the Bake Parkway Property to the Venture shall be paid for by the Venture. The parties hereby acknowledge and agree that the Agreed
Value of the Bake Parkway Property is and shall be deemed to be $6,857,889 for all purposes hereunder and that, upon the transfer and contribution of the Bake Parkway Property to the Venture, the Fund VIII-IX Joint Venture shall be deemed to have
made, and shall be credited with making, a Capital Contribution to the Venture in the amount of $6,857,889. 
  
 Wells OP shall be obligated and required to make certain cash Capital Contributions to the Venture to be used by the Venture for capital and tenant
improvements, leasing commissions and other improvements, renovations, refurbishments, costs and expenses necessary or required relating to the Bake Parkway Property and the transfer of such Property. It is hereby acknowledged and agreed that, as of
the date of this Agreement, Wells OP has made aggregate cash Capital Contributions to the Venture in the amount of $1,287,488. 
  
 The Venturers shall from time to time make such additional Capital Contributions to the Venture in such amounts as may be agreed to by the Venturers from
time to time. 
  
 4. 
  
 Except as specifically amended hereby, the Joint Venture Agreement shall
continue in full force and effect. 
  

 - 2 - 

 IN WITNESS WHEREOF, the undersigned Venturers have executed and entered into this Amendment to and
Clarification of Joint Venture Agreement of Fund VIII-IX-REIT Joint Venture and Agency Agreement intended to be effective as of the 15th day of June, 2000. 
  

			
	 Signed, sealed and delivered
 in the presence of:
  
  
 /s/ Mary Schubert

 Unofficial Witness
  
 /s/ Martha Jean Cory

 Notary Public
	 	 WELLS OPERATING PARTNERSHIP, L.P.
 a Delaware limited
partnership
  
 By: Wells Real Estate Investment Trust, Inc.,
 a Maryland corporation, as General Partner
  
 By:   /s/ Leo F. Wells, III

 Title: President

	  
 Signed, sealed and
delivered
 in the presence of:
  
  
 /s/ Mary
Schubert

 Unofficial Witness
  
 /s/ Martha Jean Cory

 Notary Public
  
	 	  
 FUND VIII AND FUND IX ASSOCIATES
  
 By: Wells Real Estate Fund VIII, L.P., a Georgia
         limited partnership
  
         By: Wells Partners, L.P., a Georgia limited
                 partnership, as General Partner
  

                By: Wells Capital, Inc., a Georgia
                         corporation, as General
Partner
  
                         By:   /s/ Leo F. Wells, III

                         Title:
President

	 Signed, sealed and delivered
 in the presence of:
  
  
 /s/ Mary Schubert

 Unofficial Witness
  
 /s/ Martha Jean Cory

 Notary Public
	 	  
  
  

 
 By:   /s/ Leo F. Wells, III

 LEO F. WELLS, III, a General Partner

  

 - 3 - 

			
	 Signed, sealed and delivered
 in the presence
of:
  
 /s/ Mary Schubert

 Unofficial Witness
  
 /s/ Martha Jean Cory

 Notary Public
	 	 By: Wells Real Estate Fund IX, L.P., a Georgia
         limited partnership
  
         By: Wells Partners, L.P., a Georgia limited
                 partnership, as General Partner
  
                 By: Wells Capital, Inc., a Georgia
                         corporation, as General
Partner
  
                         By:   /s/ Leo F. Wells, III

                         Title:
President

  

			
	 Signed, sealed and delivered
 in the presence
of:
  
 /s/ Mary Schubert

 Unofficial Witness
  
 /s/ Martha Jean Cory

 Notary Public
	 	  
         By:   /s/ Leo
F. Wells, III

                 LEO F. WELLS, III, a General Partner

  
  

 - 4 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]